Article
Experimental anti‐angiogenesis causes upregulation of genes associated with poor survival in glioblastoma
18 Dec 2007
Abstract excerpt
Vascular endothelial growth factor (VEGF) inhibitors are the most promising anti-angiogenic agents used increasingly in the clinic. However, to be efficient, anti-VEGF agents need to be associated with classic chemotherapy. Exploring gene regulation in tumor cells during anti-angiogenesis might help to comprehend the molecular basis of response to treatment. To generate a defined anti-angiogenic condition in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
